These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 26848975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
    Neukam K, Espinosa N, Collado A, Delgado-Fernández M, Jiménez-Aguilar P, Rivero-Juárez A, Hontañón-Antoñana V, Gómez-Berrocal A, Ruiz-Morales J, Merino D, Carrero A, Téllez F, Ríos MJ, Hernández-Quero J, de Lagarde-Sebastián M, Pérez-Camacho I, Vera-Méndez F, Macías J, Pineda JA, hEPAtic Study Group.
    PLoS One; 2016; 11(5):e0155842. PubMed ID: 27195797
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Macías J, Liverey Study Investigator Team.
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [Abstract] [Full Text] [Related]

  • 5. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
    Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA, COINS Study Team.
    HIV Clin Trials; 2012 Apr; 13(2):61-9. PubMed ID: 22510353
    [Abstract] [Full Text] [Related]

  • 6. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.
    Neukam K, Espinosa N, Merino D, Rivero-Juárez A, Carrero A, Ríos MJ, Ruiz-Morales J, Gómez-Berrocal A, Téllez F, Díaz-Menéndez M, Collado A, Pérez-Camacho I, Delgado-Fernández M, Vera-Méndez F, Pineda JA.
    J Int AIDS Soc; 2014 Apr; 17(4 Suppl 3):19631. PubMed ID: 25394135
    [Abstract] [Full Text] [Related]

  • 7. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD.
    JAMA; 2000 Jan 05; 283(1):74-80. PubMed ID: 10632283
    [Abstract] [Full Text] [Related]

  • 8. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study.
    Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenguer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, Quiros-Roldan E, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC, Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
    Ann Intern Med; 2017 Jan 03; 166(1):9-17. PubMed ID: 27750294
    [Abstract] [Full Text] [Related]

  • 9. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, A5288 Team.
    Lancet HIV; 2019 Sep 03; 6(9):e588-e600. PubMed ID: 31371262
    [Abstract] [Full Text] [Related]

  • 10. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V.
    J Antimicrob Chemother; 2010 Mar 03; 65(3):543-7. PubMed ID: 20032006
    [Abstract] [Full Text] [Related]

  • 11. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC, Tsai HC, Wu KS, Sy CL, Chen JK, Chen YS, Lee SS.
    J Microbiol Immunol Infect; 2016 Aug 03; 49(4):546-53. PubMed ID: 25440980
    [Abstract] [Full Text] [Related]

  • 12. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
    Rivero A, Camacho A, Pérez-Camacho I, Torre-Cisneros J.
    Enferm Infecc Microbiol Clin; 2008 Dec 03; 26 Suppl 17():45-8. PubMed ID: 20116617
    [Abstract] [Full Text] [Related]

  • 13. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
    Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA, Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    AIDS Patient Care STDS; 2011 Jul 03; 25(7):395-402. PubMed ID: 21688986
    [Abstract] [Full Text] [Related]

  • 14. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
    Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, Quiros-Roldan E, Sighinolfi L, Ladisa N, Di Pietro M, Zoncada A, Di Filippo E, Gori A, Nasta P, Torti C, Italian MASTER Cohort.
    J Acquir Immune Defic Syndr; 2015 Jul 01; 69(3):312-8. PubMed ID: 25723139
    [Abstract] [Full Text] [Related]

  • 15. Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
    Crespo M, Navarro J, Moreno S, Sanz J, Márquez M, Zamora J, Ocampo A, Iribaren JA, Rivero A, Llibre JM.
    Enferm Infecc Microbiol Clin; 2017 Oct 01; 35(8):493-498. PubMed ID: 27061975
    [Abstract] [Full Text] [Related]

  • 16. Hepatic profile analyses of tipranavir in Phase II and III clinical trials.
    Mikl J, Sulkowski MS, Benhamou Y, Dieterich D, Pol S, Rockstroh J, Robinson PA, Ranga M, Stern JO.
    BMC Infect Dis; 2009 Dec 14; 9():203. PubMed ID: 20003457
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
    Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E.
    BMC Public Health; 2010 Mar 01; 10():105. PubMed ID: 20193053
    [Abstract] [Full Text] [Related]

  • 19. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.
    Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A, ICONA Foundation Study Group.
    J Antimicrob Chemother; 2019 Nov 01; 74(11):3295-3304. PubMed ID: 31504633
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A, Icona Foundation Study Group.
    Infection; 2017 Aug 01; 45(4):521-528. PubMed ID: 28477212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.